Yang Y - Search Results

1

Modulating the function of ABCB1: in vitro and in vivo characterization of sitravatinib, a tyrosine kinase inhibitor.

Yang Y, Ji N, Cai CY, Wang JQ, Lei ZN, Teng QX, Wu ZX, Cui Q, Pan Y, Chen ZS. Yang Y, et al. Cancer Commun (Lond). 2020 Jul;40(7):285-300. doi: 10.1002/cac2.12040. Epub 2020 Jun 11. Cancer Commun (Lond). 2020. PMID: 32525624 Free PMC article.

2

Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells.

Ji N, Yang Y, Cai CY, Lei ZN, Wang JQ, Gupta P, Shukla S, Ambudkar SV, Kong D, Chen ZS. Ji N, et al. Among authors: yang y. Cancer Lett. 2019 Jan;440-441:82-93. doi: 10.1016/j.canlet.2018.10.007. Epub 2018 Oct 10. Cancer Lett. 2019. PMID: 30315846 Free PMC article.

3

VS-4718 Antagonizes Multidrug Resistance in ABCB1- and ABCG2-Overexpressing Cancer Cells by Inhibiting the Efflux Function of ABC Transporters.

Ji N, Yang Y, Cai CY, Lei ZN, Wang JQ, Gupta P, Teng QX, Chen ZS, Kong D, Yang DH. Ji N, et al. Among authors: yang dh, yang y. Front Pharmacol. 2018 Oct 30;9:1236. doi: 10.3389/fphar.2018.01236. eCollection 2018. Front Pharmacol. 2018. PMID: 30425643 Free PMC article.

4

Ulixertinib (BVD-523) antagonizes ABCB1- and ABCG2-mediated chemotherapeutic drug resistance.

Ji N, Yang Y, Lei ZN, Cai CY, Wang JQ, Gupta P, Xian X, Yang DH, Kong D, Chen ZS. Ji N, et al. Among authors: yang dh, yang y. Biochem Pharmacol. 2018 Dec;158:274-285. doi: 10.1016/j.bcp.2018.10.028. Epub 2018 Oct 26. Biochem Pharmacol. 2018. PMID: 30431011

5

Gaseous signaling molecules and their application in resistant cancer treatment: from invisible to visible.

Cui Q, Yang Y, Ji N, Wang JQ, Ren L, Yang DH, Chen ZS. Cui Q, et al. Among authors: yang dh, yang y. Future Med Chem. 2019 Feb;11(4):323-336. doi: 10.4155/fmc-2018-0403. Epub 2019 Feb 25. Future Med Chem. 2019. PMID: 30802141 Review.

6

Tepotinib reverses ABCB1-mediated multidrug resistance in cancer cells.

Wu ZX, Teng QX, Cai CY, Wang JQ, Lei ZN, Yang Y, Fan YF, Zhang JY, Li J, Chen ZS. Wu ZX, et al. Among authors: yang y. Biochem Pharmacol. 2019 Aug;166:120-127. doi: 10.1016/j.bcp.2019.05.015. Epub 2019 May 9. Biochem Pharmacol. 2019. PMID: 31078601

7

Glesatinib, a c-MET/SMO Dual Inhibitor, Antagonizes P-glycoprotein Mediated Multidrug Resistance in Cancer Cells.

Cui Q, Cai CY, Gao HL, Ren L, Ji N, Gupta P, Yang Y, Shukla S, Ambudkar SV, Yang DH, Chen ZS. Cui Q, et al. Among authors: yang dh, yang y. Front Oncol. 2019 Apr 25;9:313. doi: 10.3389/fonc.2019.00313. eCollection 2019. Front Oncol. 2019. PMID: 31106148 Free PMC article.

8

Midostaurin Reverses ABCB1-Mediated Multidrug Resistance, an in vitro Study.

Ji N, Yang Y, Cai CY, Wang JQ, Lei ZN, Wu ZX, Cui Q, Yang DH, Chen ZS, Kong D. Ji N, et al. Among authors: yang dh, yang y. Front Oncol. 2019 Jun 18;9:514. doi: 10.3389/fonc.2019.00514. eCollection 2019. Front Oncol. 2019. PMID: 31275850 Free PMC article.

9

Chk1 Inhibitor MK-8776 Restores the Sensitivity of Chemotherapeutics in P-glycoprotein Overexpressing Cancer Cells.

Cui Q, Cai CY, Wang JQ, Zhang S, Gupta P, Ji N, Yang Y, Dong X, Yang DH, Chen ZS. Cui Q, et al. Among authors: yang dh, yang y. Int J Mol Sci. 2019 Aug 22;20(17):4095. doi: 10.3390/ijms20174095. Int J Mol Sci. 2019. PMID: 31443367 Free PMC article.

10

Tivantinib, A c-Met Inhibitor in Clinical Trials, Is Susceptible to ABCG2-Mediated Drug Resistance.

Wu ZX, Yang Y, Teng QX, Wang JQ, Lei ZN, Wang JQ, Lusvarghi S, Ambudkar SV, Yang DH, Chen ZS. Wu ZX, et al. Among authors: yang dh, yang y. Cancers (Basel). 2020 Jan 12;12(1):186. doi: 10.3390/cancers12010186. Cancers (Basel). 2020. PMID: 31940916 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

110,583 results

Search Page

Filters